Occidental Asset Management LLC lifted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 25.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,629 shares of the biopharmaceutical company’s stock after acquiring an additional 2,157 shares during the quarter. Occidental Asset Management LLC’s holdings in Gilead Sciences were worth $718,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Parnassus Investments CA lifted its holdings in Gilead Sciences by 21.2% during the 1st quarter. Parnassus Investments CA now owns 13,074,555 shares of the biopharmaceutical company’s stock worth $849,976,000 after buying an additional 2,288,767 shares in the last quarter. Sanders Capital LLC lifted its holdings in Gilead Sciences by 2.1% during the 2nd quarter. Sanders Capital LLC now owns 11,526,033 shares of the biopharmaceutical company’s stock worth $842,146,000 after buying an additional 234,100 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. lifted its holdings in Gilead Sciences by 3.3% during the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 5,213,760 shares of the biopharmaceutical company’s stock worth $338,947,000 after buying an additional 167,292 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in Gilead Sciences by 1.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 5,129,197 shares of the biopharmaceutical company’s stock worth $320,822,000 after buying an additional 51,905 shares in the last quarter. Finally, LSV Asset Management lifted its holdings in Gilead Sciences by 0.8% during the 1st quarter. LSV Asset Management now owns 4,686,501 shares of the biopharmaceutical company’s stock worth $304,669,000 after buying an additional 37,464 shares in the last quarter. 78.87% of the stock is currently owned by institutional investors and hedge funds.

In other news, EVP Brett A. Pletcher sold 7,200 shares of the stock in a transaction dated Tuesday, July 23rd. The shares were sold at an average price of $65.07, for a total transaction of $468,504.00. Following the completion of the transaction, the executive vice president now directly owns 34,398 shares in the company, valued at approximately $2,238,277.86. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Brett A. Pletcher sold 5,816 shares of the stock in a transaction dated Tuesday, June 18th. The stock was sold at an average price of $68.75, for a total transaction of $399,850.00. Following the transaction, the executive vice president now owns 27,198 shares of the company’s stock, valued at $1,869,862.50. The disclosure for this sale can be found here. 0.20% of the stock is currently owned by corporate insiders.

GILD stock traded down $0.14 during trading hours on Thursday, reaching $62.98. 271,972 shares of the stock were exchanged, compared to its average volume of 6,220,770. The firm’s 50-day simple moving average is $66.33. The company has a market cap of $81.03 billion, a P/E ratio of 10.24, a price-to-earnings-growth ratio of 3.04 and a beta of 1.16. The company has a debt-to-equity ratio of 1.13, a quick ratio of 3.67 and a current ratio of 3.76. Gilead Sciences, Inc. has a 12 month low of $60.32 and a 12 month high of $79.61.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.68 by $0.14. The firm had revenue of $5.69 billion during the quarter, compared to analysts’ expectations of $5.54 billion. Gilead Sciences had a return on equity of 37.12% and a net margin of 26.64%. The company’s revenue was down 2.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.91 EPS. Equities analysts expect that Gilead Sciences, Inc. will post 6.65 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, September 27th. Shareholders of record on Friday, September 13th will be issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 4.00%. The ex-dividend date is Thursday, September 12th. Gilead Sciences’s dividend payout ratio (DPR) is presently 40.98%.

Several brokerages have commented on GILD. BidaskClub cut shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Wednesday, June 5th. Morgan Stanley set a $82.00 target price on shares of Gilead Sciences and gave the company a “hold” rating in a research report on Monday, July 15th. Royal Bank of Canada upgraded shares of Gilead Sciences from an “outperform” rating to a “top pick” rating and set a $91.00 target price for the company in a research report on Monday, July 29th. Mizuho set a $88.00 target price on shares of Gilead Sciences and gave the company a “buy” rating in a research report on Monday, July 15th. Finally, Evercore ISI reiterated a “buy” rating on shares of Gilead Sciences in a research report on Friday, May 17th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, sixteen have issued a buy rating and two have issued a strong buy rating to the company. Gilead Sciences presently has an average rating of “Buy” and an average price target of $82.29.

About Gilead Sciences

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Featured Article: Price Target

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.